Eledon Pharmaceuticals, INC

Eledon Pharmaceuticals reported strong Q2 2026 results, with successful FDA meetings for its Phase 3 kidney transplant trial and promising clinical data for tegoprubart.

Eledon Pharmaceuticals announced its full year 2025 financial results and significant clinical progress for its lead drug candidate, tegoprubart, across multiple transplantation programs.

Eledon Pharmaceuticals exchanged 4,203,764 common shares for pre-funded warrants with Coastlands Capital Partners LP, restructuring an existing equity position.

Eledon Pharmaceuticals announced its third quarter 2025 financial results and positive Phase 2 BESTOW trial data for tegoprubart, supporting its advancement into Phase 3 development for kidney transplant rejection prevention.

Eledon Pharmaceuticals, Inc. announced an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $46.5 million for clinical development and general corporate purposes.

Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart in kidney transplant rejection prevention, highlighting a favorable safety profile and plans for Phase 3 development, alongside a preliminary cash balance of $93.4 million.

Eledon Pharmaceuticals reported a wider net loss for Q1 2026, driven by increased manufacturing costs and R&D expenses, while cash reserves remain substantial.

Eledon Pharmaceuticals reports a significant net loss in Q3 2025, alongside mixed Phase 2 kidney transplant trial results and substantial capital raises to fund ongoing operations.

Eledon Pharmaceuticals reported a significantly reduced net loss for Q2 2025, driven by a decrease in warrant liabilities and strategic focus on kidney transplantation programs, while noting the need for additional financing for its ALS program.

Eledon Pharmaceuticals, Inc. filed an amended quarterly report to restate prior financial statements due to accounting errors, while reporting reduced net losses and progress in clinical trials for its lead drug candidate, tegoprubart.

Eledon Pharmaceuticals announces its Q1 2025 financial results, focusing on the advancement of its kidney transplantation program and ongoing clinical trials.

Eledon Pharmaceuticals reported a net income of $77 million for the third quarter of 2024, primarily driven by a gain in the fair value of warrant liabilities, while also detailing ongoing clinical trials and financial activities.

Eledon Pharmaceuticals' 2025 annual report details promising clinical trial results for tegoprubart in kidney and islet cell transplantation, alongside ongoing financial losses and the need for additional capital.

Eledon Pharmaceuticals amends its 2024 Annual Report to restate prior financial statements due to accounting errors, while highlighting progress in its kidney transplantation and islet cell programs and ongoing capital raises.

Eledon Pharmaceuticals' 2024 10-K filing emphasizes kidney transplantation program advancements and ongoing clinical trials while navigating financial losses and future funding needs.

Eledon Pharmaceuticals has restated its financial statements for fiscal year 2023 and several interim periods due to an accounting error related to the classification of certain warrants, also identifying a material weakness in internal controls.

Eledon Pharmaceuticals has filed an amendment to its 2023 annual report to include required information not available at the time of the original filing.

Eledon Pharmaceuticals' 10-K filing highlights a strategic shift towards kidney transplant programs while facing substantial doubt about its ability to continue as a going concern.

David-Alexandre C Gros, Chief Executive Officer and a Director of Eledon Pharmaceuticals, Inc., reported multiple transactions in common stock on July 31, 2026.

Steven Perrin, President and a Director of Eledon Pharmaceuticals, Inc., reported multiple transactions in common stock on July 31, 2026.

Eledon Pharmaceuticals Director John S. McBride acquired 3,430 shares of common stock through the settlement of restricted stock units.

Eledon Pharmaceuticals Director Jan Hillson acquired 3,430 shares of common stock through the settlement of vested restricted stock units.

Eledon Pharmaceuticals Director Allan Kirk converted 3,430 restricted stock units into common stock on January 10, 2026, increasing his direct beneficial ownership.

Eledon Pharmaceuticals Director Keith Katkin converted 8,575 restricted stock units into common stock on January 10, 2026.

Eledon Pharmaceuticals announces its 2026 Annual Meeting of Stockholders to elect directors, increase authorized shares, and ratify its auditor.

Eledon Pharmaceuticals is holding its annual stockholder meeting on June 10, 2025, seeking approval for key proposals including increasing authorized common stock and officer exculpation.

Eledon Pharmaceuticals is asking stockholders to vote on proposals to increase authorized shares and provide liability protection for officers at the upcoming annual meeting.

Eledon Pharmaceuticals will hold its annual stockholders meeting on July 10, 2024, to elect directors, approve an amendment to the 2020 Incentive Plan, and ratify the appointment of its accounting firm.

Eledon Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders to elect directors, approve an amendment to the 2020 Long Term Incentive Plan, and ratify the appointment of its independent auditor.

Vanguard Capital Management has reported a beneficial ownership of 5.05% in Eledon Pharmaceuticals Inc., holding 3,898,446 shares.

BlackRock, Inc. has reported beneficial ownership of 5.8% of Eledon Pharmaceuticals, Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Eledon Pharmaceuticals Inc. following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership in Eledon Pharmaceuticals, Inc. has fallen to 4.6% of common stock.

Coastlands Capital and its affiliates, including Matthew D. Perry, have disclosed a significant passive stake in Eledon Pharmaceuticals, Inc., reaching up to 5.98% of common stock.

The Vanguard Group has reported a 5.54% beneficial ownership stake in Eledon Pharmaceuticals Inc., holding over 3.3 million shares of common stock.